Geron to Announce Second Quarter 2024 Financial Results on August 8, 2024
Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
FDA signs off on Geron`s long-awaited blood cancer drug Rytelo
Geron Announces FDA Approval of RYTELO™ (imetelstat), a First-in-Class Telomerase Inhibitor, for the Treatment of Adult Patients with Lower-Risk MDS with Transfusion-Dependent Anemia
Geron Announces FDA Approval of RYTELO™ (imetelstat), a First-in-Class Telomerase Inhibitor, for the Treatment of Adult Patients with Lower-Risk MDS with Transfusion-Dependent Anemia
Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
In the lead-up to the likely approval of Geron’s drug to treat certain types of anemia, drug pricing watchdog the Institute for Clinical and Economic Review said Thursday that the drug would not be cost-effective at the potential price of $250,000 per year.
Geron Corporation Reports First Quarter 2024 Financial Results and Business Highlights
Geron to Announce First Quarter 2024 Financial Results on May 2, 2024
Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)